Aidoc vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aidoc is an AI radiology platform with FDA-cleared algorithms that detect and flag critical findings in medical scans, helping radiologists prioritize urgent cases.
About
Aidoc is an Israeli-American AI medical imaging company founded in 2016 that has built a comprehensive AI radiology platform with the largest portfolio of FDA-cleared imaging algorithms in the market. The platform integrates with radiology workflow systems to automatically analyze incoming scans, detect critical findings across multiple conditions, and prioritize worklists so radiologists review the most urgent cases first rather than working strictly in order of arrival. Aidoc's algorithms cover a broad range of conditions across multiple anatomical regions including intracranial hemorrhage, pulmonary embolism, incidental pulmonary nodules, and spine fractures. The company raised over $140M and is deployed at over 1,000 healthcare sites worldwide. Aidoc's aiOS platform enables third-party AI algorithms to run alongside its own models, creating an open ecosystem for AI in radiology. The company serves radiology departments seeking to improve throughput, reduce missed findings, and support radiologists managing increasing imaging volumes. Aidoc positions its platform as an AI operating system for radiology rather than a collection of point solutions, enabling comprehensive AI coverage across an entire radiology practice.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.